Literature DB >> 23867507

Role of radiotherapy in adrenocortical carcinoma.

Jennifer Ho1, Baris Turkbey, Maureen Edgerly, Meghna Alimchandani, Martha Quezado, Kevin Camphausen, Tito Fojo, Aradhana Kaushal.   

Abstract

PURPOSE: Adrenocortical carcinoma (ACC) is a rare and highly malignant tumor usually diagnosed in an advanced stage. Radiation therapy has been a poorly studied and underutilized therapeutic option.
METHODS: This retrospective analysis reviewed treatment courses for 14 patients with pathologically confirmed ACC treated between 1997 and 2012. Two patients were treated adjuvantly following surgery, and 12 were treated with palliative intent. Patients presented with stage II (n = 4), stage III (n = 7), and stage IV (n = 3) disease. Patients had a mean age of 51.5 years. Ten patients received chemotherapy before radiotherapy (RT), and 12 patients received surgery before RT, before receiving radiation at a mean of 17.8 months after diagnosis.
RESULTS: In total, 20 sites were treated, 2 of which were in an adjuvant setting, and 18 of which were for palliative indications in 12 patients as follows: (1) pain/neuropathy (n = 10), (2) prophylactic treatment of asymptomatic recurrences (n = 3), and (3) prevention of imminent metastatic complications (n = 2), hemoptysis (n = 1), severe mass effect (n = 1), and brain metastasis (n = 1). Sites were treated to a median dose of 36.3 Gy (range, 17.5-60 Gy) in a median of 2.5 Gy/fraction (range, 1.8-4 Gy). At a mean follow-up of 22.0 months for the 2 patients given adjuvant RT, 1 patient did not have a local recurrence during a 14.3-month period of follow-up, and the other had a local recurrence 14.5 months after RT. At a mean follow-up of 11.3 months for the 12 patients receiving palliative RT, 10 patients had either a clinical or radiographic response. Of the courses of palliative RT that had adequate radiographic follow-up, 4 treatments (27%) resulted in a partial response. Eleven treatments (73%) that were able to be evaluated resulted in clinical improvement. Acute Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer toxicities observed in 7 patients included 3 grade 1, 4 grade 2, and 1 grade 3. No patient had acute toxicity of grade 4 or greater or any Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late toxicity of grade 1 or greater. DISCUSSION: This report is one of the largest to date examining the role of modern radiation techniques in the management of ACC. We conclude that radiation can be effective in the management of metastatic ACC, palliating local symptoms, and preventing complications from large metastases. Radiation should be considered as an option in multimodality management of ACC patients.

Entities:  

Mesh:

Year:  2013        PMID: 23867507     DOI: 10.1097/PPO.0b013e31829e3221

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  7 in total

1.  Adrenocortical carcinoma mimicking lung cancer and responding to vinorelbine/carboplatin and pemetrexed/carboplatin.

Authors:  Oluf Dimitri Røe; Per Arne Oppegaard; Mona-Elisabeth Revheim; Aud Svindland
Journal:  BMJ Case Rep       Date:  2014-11-12

Review 2.  Adrenocortical carcinoma: patterns of care and role of adjuvant radiation therapy-a population-based study and review of the literature.

Authors:  S Atallah; H Al-Assaf; Y Xu; S El-Sayed
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

3.  Brain metastasis in patients with adrenocortical carcinoma: a clinical series.

Authors:  Mauricio Burotto; Nishant Tageja; Avi Rosenberg; Sowmya Mahalingam; Martha Quezado; Margarita Velarde; Maureen Edgerly; Tito Fojo
Journal:  J Clin Endocrinol Metab       Date:  2014-11-20       Impact factor: 5.958

4.  High TNFSF13B expression as a predictor of poor prognosis in adrenocortical carcinoma.

Authors:  Yongxin Mao; Parehe Alimu; Chenghe Wang; Wenming Ma; Ran Zhuo; Fukang Sun
Journal:  Transl Androl Urol       Date:  2021-08

5.  Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience.

Authors:  Johnathan Arnon; Simona Grozinsky-Glasberg; Kira Oleinikov; David J Gross; Asher Salmon; Amichay Meirovitz; Ofra Maimon
Journal:  J Endocr Soc       Date:  2022-07-26

6.  The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation.

Authors:  Irene Tizianel; Mario Caccese; Francesca Torresan; Giuseppe Lombardi; Laura Evangelista; Filippo Crimì; Matteo Sepulcri; Maurizio Iacobone; Marta Padovan; Francesca Galuppini; Vittorina Zagonel; Carla Scaroni; Filippo Ceccato
Journal:  Cancers (Basel)       Date:  2022-08-12       Impact factor: 6.575

7.  Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study.

Authors:  Lidia Cerquetti; Barbara Bucci; Giulia Carpinelli; Pina Lardo; Antonella Proietti; Raffaele Saporito; Guido Rindi; Elisa Petrangeli; Vincenzo Toscano; Antonio Stigliano
Journal:  Cancers (Basel)       Date:  2019-11-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.